David Whitlock of AOBiome | Q&A
Chemical engineer David Whitlock has made a splash in the media as of late, due to his lack of “splash”—as in the man hasn’t bathed in 12 years. The reason behind such a choice? David is working to d [...]
How Bell Biosystems is using naturally magnetic bacteria to track cell therapies
With FDA calling for non-invasive new tracking systems to accompany cell therapies, Bell Biosystems Inc. wants its Magnelle trackers to become the technology of choice. While the magnetic organelles' [...]
Amarantus Announces Issuance of Australian Patent
Covering Eltoprazine Treatment of Parkinson’s Disease and Alzheimer’s Disease Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product c [...]
Blueprint Genetics Plans to Boost Inherited Disease Panel Portfolio Next Year
Finnish hereditary disease diagnostics firm Blueprint Genetics plans to significantly expand its portfolio of clinical gene panel tests next year, and in the meantime has been pushing into new territo [...]
Symic Biomedical Selects Osteoarthritis Clinical Candidate
Symic Biomedical, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), today announced the selection of SB-061 as the company's [...]
A guy who hasn’t showered in 12 years just helped launch a skin care company
Forgoing a shower, even for a day, makes some people want to hide from society and double up on the deodorant. For Dave Whitlock, this is simply life as usual.The chemical engineer and MIT grad decide [...]
A new dawn for cataracts
On Thursday, November 6, scientists from ViewPoint Therapeutics published an article titled "Pharmacological chaperone for α-crystallin partially restores transparency in cataract models" in Science M [...]
Symic Biomedical Advances First Product Candidate, SB-030, Into Clinical Development
Symic Biomedical, a clinical-stage biotherapeutics platform company developing compounds that target the extracellular matrix (ECM), today announced the treatment of the first patient in its Phase 1/2 [...]
Amarantus seeks US FDA orphan drug status for eltoprazine
Amarantus Bioscience Holdings, Inc., a biotechnology company, has submitted a request to the US FDA for orphan drug designation (ODD) for eltoprazine in the treatment of levodopa-induced dyskinesia ( [...]
Military researchers to conduct trial of Amarantus’s “engineered skin substitute”
Cooperative research and development efforts with the military, universities and the biotech industry can potentially lead to advancements in the treatment of severe wounds. Biotech companies with re [...]